Cancer Family
Notochordal Tumor
CI-CAN-00000294Explore in graph →
Non-malignant15 active trials1 evidence items
- NCIt
- C7063
Loading cancer entity…
Cancer Family
CI-CAN-00000294Explore in graph →
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05041127 | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT00496119 | Proton Beam Therapy for Chordoma Patients | active not recruiting | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06957327 | A Study of ERAS-601 in People With Chordoma | active not recruiting | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06787664 | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma | active not recruiting | Phase 2 | 27 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03083678 | Afatinib in Locally Advanced and Metastatic Chordoma | completed | Phase 2 | 43 | Leiden University Medical CenterOTHER | 3 | Feb 13, 2025 | clinicaltrials |
| NCT06794645 | Pembrolizumab and Pemetrexed for Progressive Chordoma | recruiting | Phase 2 | 21 | Saint John's Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02383498 | QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | completed | Phase 2 | 24 | NantCell, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | completed | Phase 2 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | unknown | Phase 2 | 30 | Xuanwu Hospital, BeijingOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT03595228 | BN Brachyury and Radiation in Chordoma | completed | Phase 2 | 29 | Bavarian NordicINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03110744 | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma(NCT-PMO-1601) | completed | Phase 2 | 43 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04042597 | Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma(CSSG-03) | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00592748 | Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine | completed | Phase 1 / Phase 2 | 381 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00150072 | Efficacy and Safety of Imatinib in Chordoma | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2026source: clinicaltrials